Prediction of Recurrence in Patients with Stage III Colon Cancer Using Conventional Clinicopathological Factors and Peripheral Blood Test Data: A New Analysis with Artificial Intelligence

被引:4
作者
Kamei, Yutaro [1 ]
Takayama, Tetsuro [2 ]
Suzuki, Toshiyuki [1 ]
Furihata, Kenichi [3 ]
Otsuki, Megumi [4 ]
Sadahiro, Sotaro [1 ]
机构
[1] Tokai Univ, Sch Med, Dept Surg, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan
[2] Tokai Univ, Dept Gastroenterol, Hachioji Hosp, Hachioji, Tokyo, Japan
[3] Keikokai Med Corp, P One Clin, Hachioji, Tokyo, Japan
[4] SRL Inc, West Japan Testing Dept, Tokyo, Japan
关键词
Colon cancer; Stage III; Artificial intelligence; Recurrence; Prognostic factors;
D O I
10.1159/000513414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Survival rate may be predicted by tumor-node-metastasis staging systems in colon cancer. In clinical practice, about 20 to 30 clinicopathological factors and blood test data have been used. Various predictive factors for recurrence have been advocated; however, the interactions are complex and remain to be established. We used artificial intelligence (AI) to examine predictive factors related to recurrence. Methods: The study group comprised 217 patients who underwent curative surgery for stage III colon cancer. Using a self-organizing map (SOM), an AI-based method, patients with only 23 clinicopathological factors, patients with 23 clinicopathological factors and 34 of preoperative blood test data (pre-data), and those with 23 clinicopathological factors and 31 of postoperative blood test data (post-data) were classified into several clusters with various rates of recurrence. Results: When only clinicopathological factors were used, the percentage of T4b disease, the percentage of N2 disease, and the number of metastatic lymph nodes were significantly higher in a cluster with a higher rate of recurrence. When clinicopathological factors and pre-data were used, three described pathological factors and the serum C-reactive protein (CRP) levels were significantly higher and the serum total protein (TP) levels, serum albumin levels, and the percentage of lymphocytes were significantly lower in a cluster with a higher rate of recurrence. When clinicopathological factors and post-data were used, three described pathological factors, serum CRP levels, and serum carcinoembryonic antigen levels were significantly higher and serum TP levels, serum albumin levels, and the percentage of lymphocytes were significantly lower in a cluster with a higher rate of recurrence. Conclusions: This AI-based analysis extracted several risk factors for recurrence from more than 50 pathological and blood test factors before and after surgery separately. This analysis may predict the risk of recurrence of a new patient by confirming which clusters this patient belongs to.
引用
收藏
页码:318 / 326
页数:9
相关论文
共 28 条
[1]  
Beck FK, 2002, AM FAM PHYSICIAN, V65, P1575
[2]   Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer A Systematic Review and Meta-analysis [J].
Boyne, Devon J. ;
Cuthbert, Colleen A. ;
O'Sullivan, Dylan E. ;
Sajobi, Tolulope T. ;
Hilsden, Robert J. ;
Friedenreich, Christine M. ;
Cheung, Winson Y. ;
Brenner, Darren R. .
JAMA NETWORK OPEN, 2019, 2 (05)
[3]   Serum levels of insulin-like growth factor-1 in the three months following surgery for a hip fracture in elderly: relationship with nutritional status and inflammatory reaction [J].
Campillo, B ;
Paillaud, E ;
Bories, PN ;
Noel, M ;
Porquet, D ;
Le Parco, JC .
CLINICAL NUTRITION, 2000, 19 (05) :349-354
[4]   Tissue-Infiltrating Lymphocytes as a Predictive Factor for Recurrence in Patients with Curatively Resected Colon Cancer: A Propensity Score Matching Analysis [J].
Chan, Lin Fung ;
Sadahiro, Sotaro ;
Suzuki, Toshiyuki ;
Okada, Kazutake ;
Miyakita, Hiroshi ;
Yamamoto, Seiichiro ;
Kajiwara, Hiroshi .
ONCOLOGY, 2020, 98 (10) :680-688
[5]  
DESTRI GL, WORLD J GASTROENTERO, V20, P1951
[6]  
DOLAN R, BRIT J CANCER, V119, P40
[7]  
GAWANDE A, J AM COLL SURGEONS, V204, P201
[8]   Duration of Adjuvant Chemotherapy for Stage III Colon Cancer [J].
Grothey, A. ;
Sobrero, A. F. ;
Shields, A. F. ;
Yoshino, T. ;
Paul, J. ;
Taieb, J. ;
Souglakos, J. ;
Shi, Q. ;
Kerr, R. ;
Labianca, R. ;
Meyerhardt, J. A. ;
Vernerey, D. ;
Yamanaka, T. ;
Boukovinas, I. ;
Meyers, J. P. ;
Renfro, L. A. ;
Niedzwiecki, D. ;
Watanabe, T. ;
Torri, V. ;
Saunders, M. ;
Sargent, D. J. ;
Andre, T. ;
Iveson, T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) :1177-1188
[9]  
HSU C, IEEE T NEURAL NETWOR, V17, P294
[10]   Prognostic Significance of a Systemic Inflammatory Response in Patients Undergoing Multimodality Therapy for Advanced Colorectal Cancer [J].
Inoue, Yasuhiro ;
Iwata, Takashi ;
Okugawa, Yoshinaga ;
Kawamoto, Aya ;
Hiro, Junichiro ;
Toiyama, Yuji ;
Tanaka, Koji ;
Uchida, Keiichi ;
Mohri, Yasuhiko ;
Miki, Chikao ;
Kusunoki, Masato .
ONCOLOGY, 2013, 84 (02) :100-107